News
Incyte today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback